This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Galderma Research & Development. Active years: 2014-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014-2015
Title: Stéphanie Arsonnaud: Innovator in Acne Treatment
Introduction
Stéphanie Arsonnaud is a notable inventor based in Le Rouret, France. He has made significant contributions to the field of dermatology, particularly in the treatment of acne. With a total of 2 patents to his name, Arsonnaud's work focuses on innovative therapy regimens that enhance the effectiveness of acne treatments.
Latest Patents
Arsonnaud's latest patents include a novel maintenance therapy regime for the treatment of acne-related diseases. This regimen involves administering an oral antibiotic alongside a topical fixed-dose combination of a retinoid, such as adapalene, and an anti-bacterial agent, such as benzoyl peroxide. Additionally, he has developed a concurrent therapy regimen that combines a topical fixed-dose of a retinoid and an anti-bacterial agent with a course of oral antibiotic therapy. These innovations aim to improve patient outcomes in acne treatment.
Career Highlights
Stéphanie Arsonnaud is currently associated with Galderma Research & Development, where he continues to advance his research in dermatological therapies. His work is characterized by a commitment to developing effective treatment options for patients suffering from acne-related conditions.
Collaborations
Arsonnaud collaborates with esteemed colleagues in the field, including Jean-Charles Dhuin and Nabil Kerrouche. These partnerships enhance the research and development process, leading to more comprehensive solutions for acne treatment.
Conclusion
Stéphanie Arsonnaud's contributions to acne treatment through his innovative patents and collaborations highlight his dedication to improving dermatological care. His work continues to pave the way for more effective therapies in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
